Carson City, Nevada, January 24, 2018, Cell MedX Corp. (OTCQB: CMXC), (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the observational clinical trial carried out by Dr. Richard Tytus and his team at Hamilton Medical Research Group in Hamilton, Ontario (the “Trial”) has been completed. Nutrasource Diagnostics Inc., a contract research organization, has completed the final report on the Trial and has submitted it to Health Canada for final approval.
The objective of the Trial was to assess eBalance therapy as an adjunct treatment for diabetes and related complications in Type 1 and Type 2 diabetics over three months. The secondary endpoints of the Trial observed changes from baseline in the following;
- Insulin sensitivity
- Diabetic neuropathy
- Diabetic foot pain and numbness
- Wound healing
- Blood pressure
- Kidney function
- Any other changes reported by patients
The Company is pleased to announce that all 30 subjects (100%) taking part in the Trial followed through to completion. This level of completion is considered to be unusually high, particularly since the subjects were required to come to the clinic twice a week for a period of three months after the initial screening and selection.
The Trial resulted in several encouraging trends spanning a vast array of areas including HbA1c and secondary efficacy endpoints assessing insulin resistance, insulin sensitivity, blood pressure and kidney function following eBalance treatment. On average, the mean HbA1c decreased as compared to baseline. The post-treatment glucometer reading decreased relative to pre-treatment on most visits. A trend towards a decrease in markers assessing insulin resistance including fasting blood glucose, plasma insulin and HbA1c compared to baseline was noted. A marked decrease in blood pressure as measured by systolic and diastolic blood pressure was observed. A decrease in eGFR (estimated glomerular filtration rate used to assess kidney function) was also exhibited. Lastly, in regard to general pain, the Trial revealed that some subjects, without diagnosed complications, reported feeling less pain and/or coldness or numbness in their extremities. During the Trial there were no subjects with diabetic wounds so no results were observed in this area.
The treatment was considered safe for the purposes of the Trial. There were no significant treatment-related adverse events or negative abnormalities in routine hematology, biochemistry, vital signs or physical findings for the duration of the Trial.
Dr. Terrance Owen, CEO, stated, “We are very pleased with the results of this observational clinical trial. It confirms observations that we have made in the past about the benefits of eBalance treatments. Certainly, we are considering expanding our testing to include other conditions that may be alleviated by our technology.”
William Rowe, CEO of Nutrasource, the CRO working in partnership with Cell MedX on the Trial said, “Based on the results of the study, we look forward to discussing next steps with Cell MedX to further validate these results in new clinical trials for additional indications for patient wellbeing. The results observed set a positive foundation for Cell MedX in the next stage of research and regulatory filings.”
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com
On behalf of the Board of Directors of Cell MedX Corp.
CEO & Director
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Cell MedX Corp.
For further information visit: www.cellmedx.com.
Or phone: 1-844-238-2692